Euro Falls as EU-US Tariff Deal Fuels Concerns
The euro slipped below $1.16, extending the 1.3% decline posted at the beginning of the week—the sharpest one-day drop in over two months—and hitting its weakest level since June 20.
The euro’s weak performance was attributed to investor concern that the newly announced trade deal between the US and the European Union disproportionately benefits the US.
The totality of the deal is expected to offer little to Eurozone’s economic outlook. The trade agreement has drawn strong criticism from France, while others have emphasized the potential negative impact on European exporters and, by extension, economic growth.
German businesses and politicians are shocked by the customs deal that EU executive chief Ursula von der Leyen negotiated with the US president, seen as potentially damaging to Germany’s economy.
Friedrich Merz, German Chancellor expressed his satisfaction with the agreement between the European Commission president and the US president.
While European Commission President Ursula von der Leyen praised a trade agreement signed between the EU and US on Sunday as a stabilising factor “in uncertain times,” representatives of the German economy have expressed concern.
Von der Leyen and US President Donald Trump struck a tentative trade deal to avert a potentially devastating tariff war between two of the world’s largest economies on Sunday. The majority of EU exports bound for the US will be subject to a 15% tariff.
According to a statement made by von der Leyen, this also includes billions of euros in EU investments in the US, as well as the purchase of defence equipment.
Tariffs of 15% will now apply to car exports to the US, compared to the previously announced 25%. Import duties on steel are to remain unchanged at 50%.
In Europe, rate cut expectations also shifted, with markets postponing the likelihood of a 25 basis point cut to March 2026, now pricing in a 90% chance by then. For December, the probability of a cut has fallen below 70%.
The lack of clarity regarding pharmaceutical products is particularly problematic given the complexity and diversity of the industry, encompassing everything from bulk active pharmaceutical ingredients (APIs) to finished dosage forms, medical devices, and even research and development materials.
Industry experts and trade analysts are now grappling with how these new tariffs will be applied across the vast spectrum of pharmaceutical items.
Key questions arise concerning the categorisation of combination products (drugs and devices), biologics, and novel therapies.
This ambiguity could lead to differing interpretations by customs officials in both the EU and the US, potentially causing delays, disputes, and increased compliance costs for pharmaceutical companies operating across the Atlantic.
The immediate concern is the potential impact on supply chains, pricing, and ultimately, patient access to essential medicines, as companies navigate these newly imposed financial barriers. #Euro Falls as EU-US Tariff Deal Fuels Concerns#
Naira Climbs Against Dollar as Foreign Reserves Crossed $39bn
